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MITFTranscription factors have a key role in mast cell differentiation and response of differentiated mast cells to
external stimuli. During differentiation of progenitor cells to mast cells, a role for different GATA transcription
factors in combination with PU.1 expression and downregulation of C/EBPα has been described. Notch
pathway has been proposed to have a role in mast cell development. The microphthalmia-associated
transcription factor expression is upregulated in later stages of mast cells differentiation, but it is not
expressed in the closely related basophiles. In differentiated mast cells, there is a role for transcription factors
both in determining the speciﬁc mast cell phenotype and in the response to immune stimuli such as IgE-Ag. A
large number of transcription factors, including AP-1 family proteins, microphthalmia-associated transcrip-
tion factor and STAT5, are modulated by these stimuli. These transcription factors and related protein
modulators form a complex transcription factor network. They can form stimuli regulated speciﬁc
heterodimers and common inhibitors can move from one protein to another. Transcription factors are the
key regulators of mast cell physiology. Modulation of key transcription by such means as the therapeutic
siRNAmay hopefully allow us tomodulate mast cell function, obtaining clinical beneﬁt in a variety of diseases.
This article is part of a Special Issue entitled: Mast cells in inﬂammation.cells in inﬂammation.
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Mast cells, discovered by Paul Ehrlich more than 130 years ago [1],
are evolutionarily ancient cells. Cells containing tryptase–heparin
complexes in their secretory granules have been identiﬁed in
urochordates, which ﬁrst evolved approximately 500 million years
ago. As urochordates lack B and T cells, mast cells presumably predate
the appearance of the adaptive immune system [2]. Mast cells are
remarkably versatile and are able to secrete a wide range of
molecules, such as prostaglandins, chemokines and cytokines [3].
This review focuses on the role of several key transcription factors in
mast cells.
While many molecules are involved in cellular regulation,
transcription factors are of special interest due to their ability to
directly control gene expression. Indeed, some transcription factors
may act asmaster genes, being able to totally change the phenotype of
speciﬁc cell types. An outstanding example is the ability to obtain
dedifferentiated embryonal stem cells from differentiated ﬁbroblasts
by the expression of just four transcription factors [4]. Transcription
factors also have a critical role in the regulation of most of the cellular
responses to external stimuli. In mast cells, the most physiologically
important stimulus is the immunological stimulation by IgE andantigen (IgE-Ag). Response to this stimulation is partly regulated by
speciﬁc transcription factors, as described below. The response is
regulated at the level of the immediate induction of the activity
speciﬁc transcription factors, such as rapid induction of AP-1 activity
following IgE-Ag stimulation, as well as in the regulation of the
expression of speciﬁc proteins needed for immediate response, e.g.,
the regulation by c-Fos of certain granule proteins needed for mast
cell degranulation [5].
Research on transcription factors was always thought as a basic
endeavor; however, the potential of gene manipulation by therapeu-
tic siRNA might change this perception [6]. Serious start-up
companies and many of the major pharmacologic companies are
investing heavily in this therapeutic approach and cooperate with
research groups in an effort to identify key targets. Transcription
factors are critical regulators and may constitute some of the prime
targets for therapeutics. For example, decreasing the expression of the
transcription factor C/EBPα alone is sufﬁcient to prevent the
formation of both basophiles and committed mast cells [7]. Thus,
understanding the intricacies of mast cell transcriptional regulation
will hopefully soon have tangible clinical beneﬁts.
2. Transcription factors regulating mast cell differentiation
Mast cells are derived from bone marrow precursors. Unlike other
bone marrow derived cells, mature mast cells are not present in the
blood. Mast cells are conﬁned and are found exclusively in tissues
Fig. 1. Transcription factors involved in mast cell differentiation. Different experimental
systems have yielded slightly different results. It seems that mast cells can differentiate
frommyelocytes progenitor cells (CMP or from CGP), depending upon the correct level
of expression of a GATA factor (GATA2 or 3 depending on the system analyzed) with
expression of PU.1 and following downregulation of C/EBPα which can be a result of
Hes activation by Notch2. The exact relationship of these cells with the proposed
basophile/mast progenitors (BMCP) isolated from the spleen is not clear. However, in
these cells, downregulation of C/EBPα with expression of MITF is typical for mast cells
and indeed inappropriate expression of C/EBPαwill prevent accumulation of mast cells.
GATA1 seems to be expressed in these cells and in mast cells; however, it is interesting
to note that underexpression of this factor causes shifting of bone marrow progenitor
cells towards the production of immature probably non functional mast cells; thus, all
these factors should be expressed in a timely fashion in order to get mature mast cells.
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several transcription factors is essential for their initial differentiation;
yet, other transcription factors are critically important only during
later stage of mast cell maturation.
The understanding of mast cell differentiation is derived mainly
from in vitro cultures of different stages of stem and progenitor cells.
Obviously, these in vitro studies are greatly inﬂuenced by culture
conditions, which may be substantially different from in vivo settings.
It is not trivial to pinpoint the exact progenitor cell for mast cell
development. Some studies claim that mast cell precursors develop
from the common myeloid progenitor or the granulocyte–monocyte
progenitor cells (CMP or GMP) [7], while some groups have found
that, given suitable conditions, several other cell types may differen-
tiate into mast cells [8].
2.1. GATA family transcription factors
Manipulations of transcription factors from the GATA family have
yielded some impressive results. Initial studies relating to expression
of GATA1 and GATA2 revealed expression of GATA1 in both BMMC
and mature mast cells. GATA1 knockouts die in the uterus and
therefore further studies of the function of GATA1 were performed in
mice with lower expression of this gene. Initial studies with
heterozygous knockouts for GATA1, which survive to adulthood but
have lower expression of this gene, demonstrated in the skin much
lower number of Berberine sulfate positive mast cells compared to
wild type. This observation provided a strong hint that GATA1 is
needed for full maturation of dermal mast cells [9].
Migliaccio et al. [10] and Ghinassi et al. [11] used lower expression
of GATA 1 due to lack of the ﬁrst enhancer and distal promoter of
GATA. They revealed two basic defects in mast cells in these kinds of
mice. Their ﬁrst observation is that in these kinds of mice there is a
unique trilineage progenitor cell lines committed to erythroid
megakaryocytic and mast cell types. Thus, GATA1 has a special role
in the development of mast cell progenitor cells. Furthermore, they
described in this mice morphologically abnormal Alcian blue positive
mast cells and apoptotic mast cell precursors in connective tissue and
peritoneal lavage. These results imply that GATA1 has an important
role in the ﬁnal maturation of mast cells and that probably without
this transcription factor a large number of mast cell precursors
undergo apoptosis. Other studies that added to our information
regarding GATA1 role in mast cell physiology was done by Metcalf et
al. [12]. Working with bone marrow cells from chimeric mice with
inactivated GATA1, they noted the presence of numerous colonies of
large cells which turned out to be mast cell progenitors. The majority
of the excessive numbers of mast cell progenitors in chimeric GATA1
(Plt13/+) mice were transcribing the inactive Plt13 allele of GATA1,
suggesting that GATA1 normally acts to restrict the emergence of
committed mast cell progenitors. Interestingly, Metcalf et al. did not
detect excessive number of mast cells in these mice, indicating that
the progenitor cells probably gave rise to defective mature mast cells.
These results are thus similar in their basic conclusion as to GATA1
role in mast cell physiology to those described by Ghinassi et al.
although they were obtained in a different system.
Other researchers focused on GATA2. Forced expression of the
transcription factor GATA2, together with the transcription factor
PU.1, leads to differentiation of mast cells from bone marrow derived
myeloid progenitors. However, downregulation of GATA2 in these
cells leads to formation of macrophages [13]. Differentiation of mast
cells from fetal thymocytes at the double-negative 1 (DN1) and DN2
stages by GATA3 overexpression was achieved by Taghon et al. These
mast cells were obtained through manipulations of double-negative T
cells at stages 1 or 2 by overexpression of GATA3 in the absence of
Notch signaling. Perhaps, more physiologically relevant was their
ﬁnding that DN2 thymocytes could be induced to differentiate into
mast cells by blocking Notch signaling in the presence of the cytokinesc-Kit ligand and IL-3, demonstrating that early stage thymocytes are
related to mast cells. Is this ﬁnding physiologically relevant? This is
not clear at all, and to the best of our knowledge, there have not been
any experiments demonstrating differentiation of lymphocyte pro-
genitors or early thymocytes into mast cells under any physiological
circumstances.
2.2. CMP related transcription factors
A recent review has summarized the role of different transcription
factors in mast cell development. There seems to be no single “master
gene” for mast cell development. Indeed, it seems that a combination
of the “correct” expression levels of three transcription factors is
essential for the activation of the mast cell differentiation program.
The key factors in mast cell differentiation are PU.1 and GATA2/3 since
it is not yet clear whether it is GATA3 or GATA2 and the down-
regulation of C/EBPα (Fig. 1) [14].
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and basophiles
In an effort to isolate and understand the differences betweenmast
cells and basophiles, Arinobu et al. [15] have isolated a population of
cells which are Lin−, c-Kit+ and FcγRII/IIIhiβ7hi from mouse spleen.
These cells could differentiate only into mast cells or basophiles. The
cells contained Fcε RImRNA but did not express it on their membrane.
This speciﬁc cell population, which they named basophile/mast cell
progenitors (BMCPs), was expanded in response to allergic stimuli or
helminth infection. This expansion in response to known physiolog-
ical stimulators of mast cell function provides further evidence that
BMCPs have a role in vivo. These cells were intravenously injected into
W/Wv mice, which lack endogenous mast cells and differentiated into
mature mast cells detected in the spleen and stomach. Such
localization indicated that BMCPs can provide both connective tissue
and mucosal mast cells. Analysis of transcription factors revealed that
both GATA1 and PU.1 were expressed in basophiles and mast cells as
well as in BMCP. However, the microphthalmia-associated transcrip-
tion factor (MITF), which is essential for mast cell development (see
below), was highly expressed in BMCPs as well as inmaturemast cells
but was absent in basophiles. In contrast, C/EBPα was expressed in
BMCPs at a low level and was upregulated in basophiles, while it was
signiﬁcantly downregulated in mast cells. The critical role of C/EBPα
in determining the cell fate of these cell populations was demon-
strated by overexpression of this transcription factor in mast cells,
which led to reprogramming into basophile lineage. However,
knockdown of C/EBPα in BMCPs cells induced the exclusive
development of mast cell lineage and prevented the development of
basophiles. In conclusion, the expression of C/EBPα seems to play a
major role in determining the fate of BMCP cells.
3.1. Notch as a regulator of mast cell differentiation
The studies above do not address the question of which external
cues are essential for the “correct” expression pattern of mast cell
differentiation related transcription factors. The recent study by
Sakata-Yanagimoto et al. [16] adds much to our knowledge. Sakata-
Yanagimoto et al. studied the effects of the Notch receptor mediated
signaling pathway on mast cells, which is involved in the differen-
tiation of many cell types, most notably in differentiation and
commitment of T cells and marginal zone B cells. Previously, it was
noted that mast cells express high levels of Notch2. Sakata-
Yanagimoto et al used Delta1-Fc chimeric protein—Delta 1 is one of
the ligands of Notch. They studied myeloid progenitors (CMPs) and
granulocyte–macrophage progenitors (GMPs) in vitro. Sorted CMPs or
GMPs of wild type mice were cultured with plate-ﬁxed Delta1-Fc
chimeric protein in the presence of c-Kit ligand and IL-3, which
yielded cultures highly enriched for mast cells. In the control cultures
containing similar mixture of cytokines but in the presence of control
antibody instead of a Notch ligand, the main population proved to be
granulocytes and macrophages. Under these conditions, activation of
the Notch pathway seems to favor the production of mast cells. This is
important since the commonmyeloid precursors are usually regarded
as the main source of mast cell precursors [14]. Hairy and enhancer of
split 1 (Hes-1) is a Notch responsive basic helix-loop-helix Groucho
binding transcription repressor [17]. It has been shown to mediate
Notch signaling under a variety of circumstances. Sakata-Yanagimoto
et al. analyzed gene expression of CMP and GMP 8 hours following
Notch activation noting substantial induction of Hes-1 mRNA in these
cells. Interestingly, forced expression of Hes-1 in CMP and GMP cells
led to decreased expression of C/EBPα. There was a reproducible
increase in the percentage of c-Kit+–FcεRI− progenitor cells over-
expressing Hes-1 but not of cells expressing both c-Kit and FcεRI.
Thus, the former population of cells may represent immature
precursor cells.While overexpression of Hes-1 led to the downregulation of
C/EBPα, it did not recapitulate the full effect of Notch signaling on
mast cell precursors. When Sakata-Yanagimoto et al. analyzed
GATA expression levels in the Notch pathway stimulated cells, they
noted a substantial increase in GATA3 but not in GATA2 which was
previously proposed as the critical factor in mast cell differentia-
tion. Forced expression of both Hes-1 and GATA3 together, but not
alone, led to the formation of large colonies of which 80% were mast
cells.
It seems that given the correct cytokine milieu, activation of Notch
signaling can induce a substantial increase in mast cell. Sakata-
Yanagimoto et al. describe unpublished studies of Notch2 knockout
mice indicating that these mice have normal mast cell numbers but
lower resistance to nematodes [18]. A possible interpretation is that
there may be a redundancy between different Notch receptors which
can replace Notch2 under most circumstances but not under greater
physiological stress, such as during helminth infection. Another
possibility is that Notch signaling is not essential for steady state
mast cell differentiation.
Summing up the studies described support the view that mast cells
are derived from bone marrow progenitors as a result of a shift in the
expression proﬁle of a fewkey transcription factors,which include PU.1,
GATA proteins, and C/EBPα. The exact environmental cues that lead to
the described transcription factor proﬁle are not clear yet. Cytokines
such as c-Kit ligand and IL-3 have a key role but so do different Notch
ligands and perhaps other yet unidentiﬁed factors.4. Transcription factors in differentiated mast cells
4.1. Mast cells subclasses
Like most other immune system cells, there are substantial
differences between different mast cells. Initially, it was proposed to
divide mast cells to mucosal subtype and connective tissue subtype.
With further research, it seemed that mast cell phenotypes are more
complex. In the classical experiment, Nakano et al. [19] implanted
immature mast cells into mice and demonstrated that their
phenotype, assessed mainly by analysis of proteases proﬁle, is
determined by their environment and is not predetermined. We are
aware of only one effort to systematically search for genes speciﬁc for
mast cell subtypes. In experiments performed by Tsuchiya et al. [20],
mast cells were isolated from the submucosa (sMCs) and mucosa
(mMCs) of mouse stomach sections. RNA was extracted, ampliﬁed
and subjected to microarray analysis. Known marker genes, speciﬁc
for mMCs and sMCs showed expected expression trends indicating
accuracy of the analysis. A total of 1272 genes had signiﬁcantly
different expression levels between sMCs and mMCs. The expression
of only one transcription factor, c-Fos, was signiﬁcantly higher in the
sMCs. Their results are interesting because of the proven role of this
transcription factor in mast cells. However, the exact function of c-Fos
and other transcription factors in determining tissue speciﬁc
phenotypes still need to be explored. Research on T cells revealed
several T cell subtypes capable of producing a discreet subset of
cytokines in response to TCR stimulation; yet, no such mast cell
subsets have been observed, despite the variety in mast cell
phenotypes which is determined mainly by local environmental
cues and the fact that in response to similar stimuli mast cells can
secrete different immune mediators in different environment. Most
researches in mast cells are performed in vitro, which may cause such
subsets to be missed.
Mast cells have been noted to exert opposite effects on tumor
growth [21]. Manipulation of mast cell gene expression will hopefully
induce mast cells with clear anti-tumor effects. Such efforts of have
been recently reported for neutrophiles creating neutrophiles with
anti-tumor effects [22].
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Transcription factors are key regulators of mast cell transcriptional
proﬁle and understanding their role in the speciﬁc regulation of
different effector molecules secreted from mast cells is critical for any
further efforts of changing mast cell gene expression proﬁle.
The most important stimulus of mast cells is immunological
activation by IgE-Ag. Protein kinase C (PKC) has been demonstrated to
have a major role in mediating the IgE-Ag stimulus. PKC induction
following IgE-Ag stimulation was known to induce the AP-1
transcription factor binding to the TPA response element. Rauscher
et al. [23] have demonstrated that AP-1 is composed of a heterodimer
containing v-Jun transcription factor and c-Fos. Subsequent studies
demonstrated that both Jun and Fos are not single proteins but rather
the Jun family, including c-Jun, JunB, JunD and Jun binding protein 2
(JDP2), can homodimerize or heterodimerize with other Jun family
members or bind the Fos family proteins, c-Fos, FosB, Fra-1 and Fra-2,
to form AP-1 transcription factors.
All AP-1 proteins contain a leucine zipper domain. Several other
related transcription factors can also bind Fos and Jun family
members. For example, Baumruker et al. [24] and Novotny et al.
[25] found that in mast cells, cap ‘n’ collar basic leucine zipper (CNC-
bZIP) proteins, which include NF-E2, Nrf1 and Nrf2, can bind to AP-1
proteins upon induction.
Initial studies of mast cells, carried out 20 years ago, demonstrated
that IgE-Ag and c-Kit ligand stimulated mast cells display rapid
increase in the mRNA levels of several AP-1 family members [26,27].
While both c-Jun and c-Fos are regulated by PKC, c-Jun is regulated by
protein accumulation, whereas c-Fos is regulated at the mRNA level
(Fig. 2). A complex in vitro system was used to determine the PKC
isozyme responsible for c-Fos and c-Jun regulation in mast cells [28].
Rat mast cells were chronically treated with TPA, followed by
permeabilazation of the cells with streptolysin O, reconstitution
with externally supplied recombinant PKC and induction with IgE-Ag.
c-Fos and c-Jun expression levels were analyzed. PKC epsilon and PKC
beta emerged as responsible for c-Jun and c-Fos induction in this
system.
In an attempt to better understand AP-1 complex formation, we
began studies of protein complexes containing c-Fos in activated
BMMC. Contrary to our assumption, we found that IgE-Ag induced c-
Fos is not bound to c-Jun but to a different protein. At that time, aFig. 2. Early events following IgE–antigen stimulation. The schematic cell describes the
early signaling events in mast cells within minutes after IgE–antigen stimulation.
Antigen interaction with IgE bound to high afﬁnity Fc receptors (FcεRI) activates
degranulation through various signaling cascades. Degranulation is dependent upon
the activity of PKCβ, JunB and ATF3 since knockout of these genes results in decreased
degranulation. c-Fos mRNA is rapidly transcribed after PKCβ activation. USF2, c-Jun and
MITF are regulated by the accumulation of protein (seen translated in the ribosomes).
c-Jun and USF2 accumulation is mediated through PKCβ.bHLH–leucine zipper protein which was named Fos interacting
protein (FIP) was described [29]. Co-immunoprecipitation assays
revealed that IgE-Ag activated c-Fos was bound to FIP and not to c-Jun
[30,31]. FIP was later found to be identical to the previously described
USF2, a bHLH–leucine zipper transcription factor.
PKC beta antisense was used to analyze effects on USF2 binding.
Downregulation of this protein resulted in decreased binding of USF2
to DNA in IgE-Ag stimulated cells [30]. In another study, general PKC
inhibitors were used to study the regulation of USF2. It seemed that
USF2 was regulated at the translational level as was demonstrated by
the use of polysomal proﬁling and determined that the regulator of
the translation of this protein was PKC [32] (Fig. 2).
Other groups have described the existence of other AP-1
transcription factor complexes. For example, Novotny et al. [25],
studying the IgE-Ag regulation of the TNF alpha promoter in mast
cells, have described a complex containing Nrf1, a cap ‘n’ collar
transcription factor, with c-Jun, JunD, FosB and ATF2. They also
described novel splice variants of Nrf1 in mast cells, which they
hypothesize are the reason for the differential binding of Nrf1 to AP-1
family proteins in mast cells as compared to other cells. Baumruker et
al. [24,33] also described a speciﬁc role for NFAT-1 in TNF alpha
regulation in mast cells in addition to the AP-1 complex and in
addition to a GATA factor in the regulation of IL-5. NFAT is in fact a
description of several important transcription factors. Already in
1995, it has been shown that NFAT is induced following mast cell IgE-
Ag stimulation [34]. Furthermore, this transcription factor seems to
have an important role both in the production of the cytokine IL-13
[35] and in the prevention of mast cell apoptosis following IgE-Ag
stimulation [36]. Interestingly, this is achieved by stimulation of the
prosurvival A1 gene which seems to be mast cells speciﬁc since in
macrophage this is achieved by stimulation of NFk b [36]. Thus, NFAT
transcription factors have also an important role in mast cell
regulation at least in some cases due to their ability to costimulate
gene transcription with GATA transcription factors.
ATF3 is a member of the ATF/CREB (CRE-binding protein) family,
which is a subfamily of the AP-1 group. ATF3 has been reported to
activate transcription as a heterodimer with c-Jun, whereas it
represses transcription as a heterodimer with JunD [37]. It is closely
related to the transcription factor Jun dimerization protein 2 (JDP2),
which can bind Jun and under certain circumstances downregulate it.
JDP2 can act as an inhibitor of ATF3 expression. Most recently through
the use of BMMC, it was established that BMMC lacking ATF3 have
decreased degranulation in response to IgE-Ag stimulation, whereas
IL-4 and IL-6 expression was enhanced [38]. BMMC from ATF3
deﬁcient mice are dependent on both IL-3 and c-Kit ligand induction
for their proper differentiation, as opposed to normal BMMC which
require only IL-3, probably as a result of downregulation of the AKT
pathway [38]. We have earlier demonstrated that degranulation is
impaired in PKCβ deﬁcient [39] and in c-Fos deﬁcient mast cells [5].
Similar effects were seen in JunB [40] and ATF3 knockout mast cells
[38]. However, there are differences between the cytokine proﬁles in
mast cells derived from each of these knockout mice. Both IL-6 and IL-
4 are elevated in ATF3 knockout mice, while only IL-6 is elevated in c-
Fos and Jun-B knockout mice. In contrast, substantial reduction in the
level of IgE-Ag induced IL-6 expression is demonstrated in PKCβ
knockout mice.
These results suggest that a complex network of AP-1 related
proteins is involved in the transcriptional control of activated mast
cells.
As described above, we noted that USF2 can bind to c-Fos in
activated mast cells [31]. USF2 is a transcription factor that is most
similar to the bHLH–leucine zipper transcription factors of the MiT
family. This family contains the transcription factor MITF [41]. The
MITF gene resides at the mi locus in mice and mutations of this gene
result in deafness, bone loss in dominant negative mi/mi mice, small
eyes and poorly pigmented eyes and skin and in some mutants nearly
46 S. Tshori, H. Nechushtan / Biochimica et Biophysica Acta 1822 (2012) 42–48total deﬁcit of mast cells [41,42]. As described above, MITF expression
was detected in mast cells derived from the common basophile/mast
cell committed progenitors (BMCPs) but not in basophiles [15].
MITF contains a basic domain followed by helix-loop-helix (HLH)
domain and a leucine zipper domain. The leucine zipper domain is
essential for protein–protein interaction and for DNA binding and
may allow interaction with other leucine zipper domain containing
transcription factors, such as c-Fos and USF2 [43]. Following the
identiﬁcation of the MITF gene, both its function and regulation were
studied in mast cells. Kitamura et al. demonstrated in a series of
studies (reviewed in [44,45]) that MITF regulates the expression of
various mast cell proteases (MCP), including mMCP-6, mMCP-5 (23),
the most important mast cell cytokine receptor—c-Kit, and other
enzymes such as Granzyme B.
We tried to elucidate the regulatory mechanisms of this transcrip-
tion factor. In our initial study, we demonstrated that MITF could bind
USF2 in IgE-activated mast cells [43]. Furthermore, following this
stimulation, its protein levels were increased but not its mRNA levels.
MITF hasmultiple mRNA isoforms due to the use of different promoters
and alternative splicing. MITF can be expressed from different
promoters (for example, M, A and H). The function and importance of
different MITF isoforms is not yet fully understood. Recent evidence
using transient transfection of different MITF isoforms suggest that
there is differential regulation of some of those forms and also
sometimes speciﬁc physiological roles [46,47]. For example, only cells
overexpressing MITF-e adhere to the culture ﬂask with a morphologic
appearance reminiscent of macrophages [46].
We were interested in ﬁnding proteins which regulated MITF
activity in mast cells. Using yeast two hybrid methodology, we cloned
several proteins which could bind MITF with high avidity, including
Hint-1, previously known as PKCI [48].Using luciferase assays, we
noted that this protein can inhibit MITF transcriptional activity.
Furthermore, we noted that Lysyl tRNA synthetase (LysRS), a protein
with not only a major role in translation but also a multitude of other
“moonlighting” functions [49], binds MITF. LysRS can produce the
dinucleotide Ap4A, and we demonstrated that this dinucleotide can
release Hint from MITF and allow transcriptional activation [50]. In
addition to MITF, Hint could also bind and inhibit USF2 in mast cells
[51]. We could also demonstrate that LysRS activity is regulated by
phosphorylation through MAP kinase pathway and that transfectionFig. 3. Regulation of MITF transcriptional activity. MITF has been shown to be critical for th
(MCPs). In resting mast cells, MITF transcriptional activity is regulated by several repressors,
Lysyl tRNA synthetase (LysRS) and releases MITF fromHint. Ap4A is later degraded by Ap4A h
by the sumo ligase PIAS3. Upon immunological stimulation, PIAS3 releases MITF and binds t
as c-Kit, granzyme B (GrB) and mast cell proteases (MCPs).of pseudophosphorylated LysRS increased cellular Ap4A levels [52].
Ap4A is degraded by Ap4A hydrolase (NUDT2), and this degradation
is induced by IgE-Ag activation of mast cells. Inhibition of Ap4A
hydrolase indeed induced MITF target gene expression in mast cells
[53] (Fig. 3).
Another inhibitor of MITF that was found by the use of the yeast
two hybrid system is the protein inhibitor of stat, PIAS3. It was ﬁrst
described as an inhibitor of STAT3 but serve as an inhibitor of various
transcription factors [54]. Interestingly, in IgE-Ag activated mast cells,
PIAS3 was released from activated MITF and was bound to STAT3 [55]
(Fig. 3). Whether, under physiological conditions, the released PIAS3
can also bind other major transcriptional regulators of mast cells, such
as STAT5, is not clear yet. MITF may act not only as a transcription
factor but also as a “sink” for PIAS3; thus, regulating the inhibition of
various transcription factors.6. STAT5
The JAK–STATpathwayhas a critical role in the signal transductionof
many cytokines. There are 4 known JAK proteinswhich can activate one
or more of the seven known STAT proteins. We described above the
possible interactions betweenMITF and STAT3. However, there is more
data regarding the critical role of STAT5 inmast cells. Several key stimuli
of mast cells can induce this transcription factor (there are actually two
closely related STAT5 genes and gene products). It seems that the
stimulation of this transcription factor is essential for the full IgE-Ag
mediated mast cell activation which include degranulation, cytokine
production and survival [56]. Furthermore, it seems that inmast cells c-
Kit stimulation results in STAT5 stimulation which has a critical role in
these cells unlike other cell typeswhere STAT3 is also stimulated by this
receptor [57]. Since c-Kit lackingmice are nearly devoid of mast cells, it
is not surprising to note that knockout mice of STAT5 almost lack mast
cells [58]. BMMC from thesemice could only beobtained in thepresence
of both c-KiT and IL-3 which do seem to stimulate also STAT3 [58].Thus,
STAT transcription factors andmainly STAT5 seem to have a critical role
in the survival of mast cells and their response to external stimuli.
While we have strived to describe the roles of some of the key
transcription factors in mast cells, it is obvious that we have not
described all the transcription factors active in these cells and havee regulation of several key mast cell molecules including c-Kit and mast cell proteases
including Hint and PIAS3. During mast cell activation, Ap4A synthesized by MITF bound
ydrolase (Hydro), and Hint can once again bind and repress MITF. MITF is also inhibited
he newly phosphorylated STAT3. MITF is now free to transactivate its target genes, such
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such as NFAT [36,59,60] and EGR1 [61–63].
7. Conclusion
Transcription factors have a key regulatory role in the differentiation
of mast cells, their survival and immune regulated functions. Speciﬁc
master gene with unique mast cell expression pattern has not been
found. Rather than that, it is a combination of several transcription
factors which determinemast cell differentiation, survival and function.
Differentiation of mast cells seems to be dependent upon the correct
expression pattern of a number of key transcription factors. Forced
expression of a critical transcription factor can lead to outstanding
results for example the transdifferentiation of basophiles intomast cells.
The physiological regulation of these key transcription factors in
vivo is only now beginning to be understood. It seems that some
known receptors such as those from the Notch family play a key role
also in the regulation of mast cell progenitors besides their better
characterized roles in other cells such as T cells.
In differentiated mast cells, the picture that emerges is even more
complicated. Numerous transcription factors are active in mast cells.
Their activity is modulated by external stimuli such as IgE-Ag and
cytokine receptors. Many of them are found in complexes and can
change their binding partners upon external stimulation. The possible
number of complexes is very large. New techniques allowing the
isolation of chromatin bound proteins, isolation of large protein
complexes and their analysis by mass spectrometry will provide new
data regarding the active complexes present in mast cells in vivo.
Critical for our understanding of the speciﬁc roles of transcription
factors in mast cells has been the use of knockout mice. Using these
models, it has been found out that there are differential roles even for
closely related proteins such as those from the AP-1 protein family.
Knockout mice were also instrumental for our initial understanding of
some key proteins regulating several mast cell factors such as PIAS3
regulating both STAT3 and MITF.
In order to better study in vivo mast cell speciﬁc activity of
transcription factors, it would be important to create conditional
knockout mice with mast cell speciﬁc expression and also inducible
gene regulation. Initial mice with mast cell speciﬁc gene ablation have
been described and we hope they would be soon useful for
transcription factors studies in mast cells.
Investigating the transcriptional networks controlling mast cell
function is a difﬁcult task. Yet it is crucial for our in-depth
understanding of the mast cell regulation. Hopefully, such studies
would provide us with the insights necessary for the formulation of
sophisticated therapeutic strategies of these key immune cells.
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